Dataset from A Phase 1, Open-label, Parallel-group Study To Assess The Effect Of Cyp3a5 Genotype On The Pharmacokinetics Of Maraviroc And Cyp3a5-derived Metabolites With And Without Darunavir/Cobicistat In African-american And Caucasian Healthy Volunteers
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009194
下载链接
链接失效反馈官方服务：
资源简介：
This will be an open-label, parallel group, multiple dose study in approximately 48 healthy
male or female subjects of African American and Caucasian self-reported race, to assess the
effect of CYP3A5 genotype on the PK of MVC and CYP3A5-derived metabolites. Maraviroc and
CYP3A5-derived metabolite PK will also be compared between African-Americans and Caucasians
in subjects carrying two copies of the dysfunctional CYP3A5 alleles (*3, *6, and/or *7).
创建时间：
2024-11-26
